All data are based on the daily closing price as of July 22, 2024
h

Handa Pharmaceuticals

6620.TWO
2.95 USD
-0.08
-2.64%

Overview

Last close
2.95 usd
Market cap
416.66M usd
52 week high
6.91 usd
52 week low
2.95 usd
Target price
N/A usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
N/A
Price/Book Value
N/A
Enterprise Value
N/A usd
EV/Revenue
N/A
EV/EBITDA
N/A

Key financials

Revenue TTM
N/A usd
Gross Profit TTM
N/A usd
EBITDA TTM
N/A usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
N/A usd
Net debt
N/A usd

About

Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States and China. The company provides Quetiapine XR for the treatment of Schizophrenia; and Dexlansoprazole DR capsules. It also develops ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; 505(b)(2)NDA, a therapeutic product; Tascenso ODT for the treatment of multiple sclerosis; and HND-033 and HND-027, an oncology products. In addition, the company develops HND-004, a diabetic drug; HND-032 for smoking cessation; and HND-026, a GI drug. Handa Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Tainan City, Taiwan.
  • Symbol
    6620.TWO
  • Exchange
    TWO
  • Isin
    N/A
  • Country
    Taiwan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
    Dr. Guo-Chun Song Ph.D.
  • Headquarter
    Tainan City
  • Web site
    https://www.handapharma.com.tw
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top